<DOC>
	<DOC>NCT00332488</DOC>
	<brief_summary>to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue</brief_summary>
	<brief_title>Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Nonsmokers with clinical diagnosis of Type 2 diabetes mellitus for &gt;or= to 6 months Stable regimen of metformin for &gt; or = to 1000mg/day or maximum tolerated dose) and a secretagogue &lt; or = 1/2 the maximum manufacturerrecommended daily dose without any dose adjustments within the preceding 6 wks. Fixed dose combination products of metformin and sulfonylurea are acceptable as long as each individual dose meets inclusion criteria HbA1c &gt;or= to 7.5% and &lt; or= to 11.0% BMI &lt; or = to 40kg/m2. FEV1&gt; or = to 70%, Total Lung capacity and &gt; or =80% DLco &gt; or= to 70% Treatment with any type of antidiabetic therapy, other than metformin &amp; secretagogues within the preceding 12 weeks Serum creatinine &gt; 1.4mg/dL in female subjects and &gt;1.5mg/dL in male subjects History of chronic obstructive pulmonary disease, clinically proven asthma and/or any other clinically important pulmonary function testing and/or radiologic findings Evidence of serious complications of diabetes (e.g. autonomic neuropathy)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>